Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.